A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Phase 3
Recruiting
- Conditions
- Essential HypertensionType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 276
- Registration Number
- NCT06220773
- Locations
- ๐ฐ๐ท
Severance Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"
Phase 1
Completed
- Conditions
- Essential HypertensionPrimary Hypercholesterolemia
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 58
- Registration Number
- NCT06184269
- Locations
- ๐ฐ๐ท
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT06165237
- Locations
- ๐ฐ๐ท
ChungBuk National University Hospital, Chungbuk, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
Phase 3
Recruiting
- Conditions
- Essential HypertensionPrimary Hypercholesterolemia
- Interventions
- Drug: BR1018A-1Drug: BR1018ADrug: BR1018BDrug: BR1018B-1Drug: BR1018CDrug: BR1018C-1
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 156
- Registration Number
- NCT06165250
- Locations
- ๐ฐ๐ท
Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
๐ฐ๐ทSeoul National University Boramae Medical Center, Seoul, Korea, Republic of
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
Recruiting
- Conditions
- Chronic Kidney Disease 5DSecondary Hyperparathyroidism
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 1000
- Registration Number
- NCT06126016
- Locations
- ๐ฐ๐ท
DongGuk university Ilsan hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
Observational Study to Evaluate the Safety and Efficacy of Zepzelcaโข Injection
Recruiting
- Conditions
- SCLC
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT06021483
- Locations
- ๐ฐ๐ท
Seoul National University Boramae Medical Center, Seoul, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 57
- Registration Number
- NCT06008028
- Locations
- ๐ฐ๐ท
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT06008015
- Locations
- ๐ฐ๐ท
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Recruiting
- Conditions
- HypertensionDiabetes Mellitus
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 9000
- Registration Number
- NCT05970237
- Locations
- ๐ฐ๐ท
Gachon University Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fasting Conditions in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Gastric or Duodenal Ulcers
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT05959486
- Locations
- ๐ฐ๐ท
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
ยฉ Copyright 2025. All Rights Reserved by MedPath